“Development of LY2334737, an Oral Gemcitabine Prodrug for Continuous Administration. Perspectives for the Therapy of Mature T-Cell and NK-Cell Lymphomas”. Hematology Meeting Reports 3, no. 1 (June 11, 2009). Accessed June 2, 2026. https://journals.pagepress.net/hmr/article/view/533.